Vol. 4 No. 9 (2024)
Reimbursement Recommendations

Inclisiran (Leqvio)

decorative image of the issue cover

Published September 3, 2024

Key Messages

  • CADTH recommends that Leqvio be reimbursed by public drug plans as an adjunct to lifestyle changes, including diet, to further reduce low-density lipoprotein cholesterol (LDL-C) levels in adults who are on a maximally tolerated dose (MTD) of a statin, with or without other LDL-C–lowering therapies, and who have heterozygous familial hypercholesterolemia (HeFH), if certain conditions are met.
  • Leqvio should only be covered to treat adult patients with HeFH according to the reimbursement criteria used for the PCSK9 monoclonal antibodies that are currently reimbursed by public drug plans.
  • Leqvio should only be reimbursed if prescribed in a similar manner as the PCSK9 monoclonal antibodies are prescribed, and if it does not cost more than the least expensive comparator reimbursed for the treatment of adult patients with HeFH who require additional lowering of LDL-C despite maximally tolerated statin therapy. Leqvio should not be reimbursed when used together with PCSK9 monoclonal antibodies.